Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

85.98 -0.30 (-0.35%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,385,004
Open 85.42
Bid (Size) 86.00 (1)
Ask (Size) 86.12 (2)
Prev. Close 86.28
Today's Range 84.56 - 86.46
52wk Range 73.31 - 105.07
Shares Outstanding 2,531,374,696
Dividend Yield 3.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain

Performance

YTD
-13.3%
-13.3%
1 Month
-4.6%
-4.6%
3 Month
+8.4%
+8.4%
6 Month
+3.4%
+3.4%
1 Year
-16.0%
-16.0%

More News

Read More
Earnings Scheduled For October 30, 2025
Via Benzinga
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Merck Q3 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
Via Benzinga
Topics ETFs
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Via Benzinga
Topics Economy
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
Via Benzinga
Merck’s (NYSE:MRK) Q3 Sales Top Estimates
Via StockStory
Merck & Co. Inc. (NYSE:MRK) Q3 2025 Earnings Beat Expectations Despite Stock Decline
Via Chartmill
Topics Earnings
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain
Via Investor's Business Daily
Topics Earnings Stocks
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via Investor Brand Network
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via FinancialNewsMedia
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
From Merck & Co., Inc.
Via Business Wire
Merck (MRK) Reports Earnings Tomorrow: What To Expect
Via StockStory
Topics Artificial Intelligence
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
Via Benzinga
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 Dividend-Paying Drug Stocks to Buy at a Discount
Via The Motley Fool
Topics Intellectual Property
How Is The Market Feeling About Merck & Co Inc?
Via Benzinga

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 85.98
When was Merck & Co last traded?
The last trade of Merck & Co was at 10/31/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 217.65B
How many shares of Merck & Co are outstanding?
Merck & Co has 218B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.